Harmine and Bcl-2 antagonists each elicited apoptosis as single agents, but a more profound effect was observed using combined treatment in NSCLC cells (Figure 5A and 5B, combination therapy vs. monotherapy, P < 0.05). The gene discussed is BCL2; the disease is non-small cell lung carcinoma.